Dextromethorphan and guaifenesin use must be monitored meticulously in sufferers with "lousy metabolizer" CYP2D6 enzyme concentrations and individuals who are sedated. This combination medication contains a significant median harmful dose (TD50) to median productive dose (ED50) ratio (or therapeutic index) in these sufferers. This medication is used for short term https://social-medialink.com/story3534255/a-review-of-dextromethorphan-dxm-for-sale-in-usa